XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Operating activities                
Net loss $ (5,458,101) [1],[2] $ (4,731,261) [2] $ (53,150,934) [1] $ (5,361,720) $ (10,189,362) [1] $ (58,512,654) [3] $ 27,200,000 $ 4,700,000
Adjustments to reconcile to net loss to net cash used in operating activities                
Depreciation and amortization         137,755 81,874    
Share-based compensation         3,357,859 1,352,708    
Financing costs         0 43,818,000    
Beneficial conversion feature on convertible debenture         0 427,796    
Accretion of discount on convertible debenture         0 116,147    
Change in fair value of warrants liability [1] (4,585,000)   3,497,230   (9,361,000) 3,075,400    
Change in fair value of derivative liability         (20,936) 0    
Loss on disposal of asset         0 1,381    
Gain on extinguishment of PPP Loan         0 (492,100)    
Noncash lease expense         283,251 (1,003)    
Change in operating assets and liabilities                
Accounts receivable         (74,278) (139,140)    
Inventory         322,156 (3,164,653)    
Prepaid expenses and other assets         (1,462,221) (2,209,159)    
Accounts payable         (2,409,448) 330,890    
Accrued expenses         (684,517) 1,595,165    
Deferred revenue         79,576 305,922    
Net cash used in operating activities         (20,021,165) (13,413,426)    
Investing activities                
Proceeds from sale of property and equipment         0 7,969    
Purchase of property and equipment         (317,225) 0    
Investments         (1,000,000) 0    
Net cash (used) provided in investing activities         (1,317,225) 7,969    
Financing activities                
Proceeds from Newborn Escrow Account         0 58,184,461    
Redemption of Newborn shares         0 (18,629)    
Issuance costs related to reverse recapitalization and PIPE offering         0 (3,970,657)    
Proceeds from PIPE offering         0 14,250,000    
Repayment of Newborn sponsor loans         0 (487,500)    
Repurchase of common stock from EDF         0 (6,000,000)    
Newborn cash acquired         0 50,206    
Purchase of stock from investor         0 (2,000,000)    
Payment of financing costs         0 (531,527)    
Proceeds from forward option put exercise         1,994,073 0    
Proceeds from common stock offering, net of offering costs         1,859,685 0    
Payment of finance lease Obligations         (4,425) (1,989)    
Proceeds from exercise of stock options         173,575 0    
Net cash (used) provided in financing activities         4,022,908 59,474,365    
Effect of exchange rate on cash         (54,796) 98,193    
Net increase (decrease) in cash and restricted cash         (17,370,278) 46,167,101    
Cash and restricted cash at beginning of year   $ 32,740,520   $ 2,275,895 32,740,520 2,275,895 2,275,895  
Cash and restricted cash at end of period $ 15,370,242   $ 48,442,996   15,370,242 48,442,996 $ 32,740,520 $ 2,275,895
Supplemental Disclosure of Noncash Financing Activity                
Conversion of preferred stock to common stock         0 1,679    
Conversion of debenture and accrued interest to common shares         0 3,999,435    
Conversion of shares due to reverse recapitalization         0 3,383    
Issuance of common stock for merger success fee         0 2,085,299    
Non-cash merger transaction costs         0 2,085,299    
Accrued transaction costs related to reverse recapitalization         0 189,434    
Issuance of private warrants         0 1,253,228    
Forgiveness of PPP Loan         0 492,100    
Issuance of Stonepeak and Evolve warrants         0 27,640,000    
Issuance of Stonepeak and Evolve options         0 12,584,000    
Transfer of Inventory to property and equipment         $ 87,095 $ 0    
[1] Note 2.
[2] See Note 2.
[3] Note 2.